Patient-specific HLA-I subtypes predict response to immune checkpoint blockade
Specific shared HLA-I alleles were linked to the response to immune checkpoint blockade (ICB). We aimed to identify the HLA-A subtypes associated with maximum benefit from ICB. We compiled a clinical dataset of patients who underwent a CLIA-approved germline HLA status testing as part of various adv...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2025.2462386 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849325287506968576 |
|---|---|
| author | Kyrillus S. Shohdy Jack Atherton Jessica Longland Jennifer Alison Manon Pillai Fiona Thistlethwaite |
| author_facet | Kyrillus S. Shohdy Jack Atherton Jessica Longland Jennifer Alison Manon Pillai Fiona Thistlethwaite |
| author_sort | Kyrillus S. Shohdy |
| collection | DOAJ |
| description | Specific shared HLA-I alleles were linked to the response to immune checkpoint blockade (ICB). We aimed to identify the HLA-A subtypes associated with maximum benefit from ICB. We compiled a clinical dataset of patients who underwent a CLIA-approved germline HLA status testing as part of various advanced immune and cell therapy trials undertaken at the Christie NHS Foundation Trust. A total of 285 patients were eligible for final analysis. We identified 15 HLA-A subtypes, the most common alleles being HLA-A02, HLA-A01, and HLA-A03. A02:01 showed a tumor lineage-specific distribution. One hundred and forty patients received ICB and had evaluable response status. Patients with A01 were associated with better clinical outcomes. No significant associations were observed between HLA-A subtypes and the incidence of immune-related adverse effects. HLA genotyping should be incorporated early in the diagnostic work-up of patients with solid cancers as a predictive and selective biomarker. |
| format | Article |
| id | doaj-art-cf36b4aee176463da8b58fc0051d28cb |
| institution | Kabale University |
| issn | 2162-402X |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj-art-cf36b4aee176463da8b58fc0051d28cb2025-08-20T03:48:27ZengTaylor & Francis GroupOncoImmunology2162-402X2025-12-0114110.1080/2162402X.2025.2462386Patient-specific HLA-I subtypes predict response to immune checkpoint blockadeKyrillus S. Shohdy0Jack Atherton1Jessica Longland2Jennifer Alison3Manon Pillai4Fiona Thistlethwaite5Experimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, UKExperimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, UKExperimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, UKExperimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, UKExperimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, UKExperimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, UKSpecific shared HLA-I alleles were linked to the response to immune checkpoint blockade (ICB). We aimed to identify the HLA-A subtypes associated with maximum benefit from ICB. We compiled a clinical dataset of patients who underwent a CLIA-approved germline HLA status testing as part of various advanced immune and cell therapy trials undertaken at the Christie NHS Foundation Trust. A total of 285 patients were eligible for final analysis. We identified 15 HLA-A subtypes, the most common alleles being HLA-A02, HLA-A01, and HLA-A03. A02:01 showed a tumor lineage-specific distribution. One hundred and forty patients received ICB and had evaluable response status. Patients with A01 were associated with better clinical outcomes. No significant associations were observed between HLA-A subtypes and the incidence of immune-related adverse effects. HLA genotyping should be incorporated early in the diagnostic work-up of patients with solid cancers as a predictive and selective biomarker.https://www.tandfonline.com/doi/10.1080/2162402X.2025.2462386Advanced cancerHLA subtypeimmune checkpointpredictive biomarkers |
| spellingShingle | Kyrillus S. Shohdy Jack Atherton Jessica Longland Jennifer Alison Manon Pillai Fiona Thistlethwaite Patient-specific HLA-I subtypes predict response to immune checkpoint blockade OncoImmunology Advanced cancer HLA subtype immune checkpoint predictive biomarkers |
| title | Patient-specific HLA-I subtypes predict response to immune checkpoint blockade |
| title_full | Patient-specific HLA-I subtypes predict response to immune checkpoint blockade |
| title_fullStr | Patient-specific HLA-I subtypes predict response to immune checkpoint blockade |
| title_full_unstemmed | Patient-specific HLA-I subtypes predict response to immune checkpoint blockade |
| title_short | Patient-specific HLA-I subtypes predict response to immune checkpoint blockade |
| title_sort | patient specific hla i subtypes predict response to immune checkpoint blockade |
| topic | Advanced cancer HLA subtype immune checkpoint predictive biomarkers |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2025.2462386 |
| work_keys_str_mv | AT kyrillussshohdy patientspecifichlaisubtypespredictresponsetoimmunecheckpointblockade AT jackatherton patientspecifichlaisubtypespredictresponsetoimmunecheckpointblockade AT jessicalongland patientspecifichlaisubtypespredictresponsetoimmunecheckpointblockade AT jenniferalison patientspecifichlaisubtypespredictresponsetoimmunecheckpointblockade AT manonpillai patientspecifichlaisubtypespredictresponsetoimmunecheckpointblockade AT fionathistlethwaite patientspecifichlaisubtypespredictresponsetoimmunecheckpointblockade |